174681-86-8

Basic information

• Product Name: 2-Pyridinecarboxylicacid,3-ethenyl-,methylester(9CI)
• Synonyms: 2-Pyridinecarboxylicacid,3-ethenyl-,methylester(9CI);methyl 3-vinylpicolinate
• CAS NO: 174681-86-8
• Molecular Formula: C9H9NO2
• Molecular Weight: 163.17
• Product Categories: GLYCINESCAFFOLD
• Mol File: 174681-86-8.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Pyridinecarboxylicacid,3-ethenyl-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxylicacid,3-ethenyl-,methylester(9CI)(174681-86-8)
• EPA Substance Registry System: 2-Pyridinecarboxylicacid,3-ethenyl-,methylester(9CI)(174681-86-8)

Safety Data

• Hazardous Substances Data: 174681-86-8(Hazardous Substances Data)

Upstream product

• 53636-56-9 methyl 3-bromopicolinate 
• 30683-23-9 3-bromopicolinic acid 
• 7486-35-3 tri-n-butyl(vinyl)tin 
• 81569-45-1 methyl 5-ethylthiazole-4-carboxylate 
• 62733-99-7 methyl 3-hydroxypicolinate 
• 874-24-8 3-hydroxypyridine-2-carboxylic acid 
• 157865-84-4 methyl 3-(trifluoromethylsulfonyloxy)-pyridine-2-carboxylate 

Downstream Products

• 878805-23-3 3-cyclopropylpyridine-2-carboxylic acid 
• 4116-88-5 3-ethylpicolinic acid 

Relevant articles and documents

A convenient synthesis of 3-substituted pipecolic acid methyl esters

A practical synthesis of the title compounds (3a-c, e) from commercially available 3-hydroxy-2-pyridine carboxylic acid (4) is reported. The key step in the synthetic sequence involves a Pd-catalyzed cross coupling reaction of the triflate 6 with the appr

NOVEL COMPOUNDS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.